Currently Enrolling Trials
Zomig (zolmitriptan) is a serotonin (5‑HT)1B/1D receptor agonist (triptan).
Zomig is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years and older
Adults: The efficacy of Zomig nasal spray 2.5 mg and 5 mg in the acute treatment of migraine headache with or without aura in adults was demonstrated in Study 1, a randomized, outpatient, double-blind, placebo-controlled trial.
Pediatric Patients 12 to 17 Years of Age: The efficacy of Zomig nasal spray in the acute treatment of migraine headache with or without aura in pediatrics patients 12 to 17 years of age was demonstrated in Study 2, a randomized, double-blind, placebo-controlled trial with a single-blind run-in period.
Adverse events associated with the use of zolmitriptan may include (but are not limited to) the following: Adults: unusual taste, paresthesia, dizziness, and hyperesthesia. Pediatrics: unusual taste.
Mechanism of Action
Zomig (zolmitriptan) is an oral selective 5-hydroxytryptamine (5-HT) receptor agonist that binds to human recombinant 5-HT and 5-HT receptors. It is thought that migraine symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides through nerve endings in the trigeminal system. The therapeutic effects of zolmitriptan are most likely due to the agonistic effects at the 5-HT receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.